Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 04:32 pm IST
Share
Apellis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 110.4 million compared to USD 22.06 million a year ago. Net loss was USD 140.24 million compared to USD 191.27 million a year ago. Basic loss per share from continuing operations was USD 1.17 compared to USD 1.75 a year ago.
For the nine months, revenue was USD 250.21 million compared to USD 52.76 million a year ago. Net loss was USD 440.05 million compared to USD 486.18 million a year ago. Basic loss per share from continuing operations was USD 3.73 compared to USD 4.65 a year ago.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
APELLIS PHARMACEUTICALS, INC. 
